GLP-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity, helping millions of people improve blood sugar control and achieve significant weight loss. Medications such as Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus have become household names, with many patients experiencing meaningful health benefits under the supervision of their healthcare providers.
At the same time, a growing number of patients allege they developed serious gastrointestinal complications after using these medications. Lawsuits filed across the country claim that manufacturers failed to provide adequate warnings about the risk of severe digestive injuries, including stomach paralysis, bowel obstruction, and gallbladder disease.
Plaintiffs contend that stronger warnings could have enabled patients and physicians to make more informed treatment decisions and to recognize potential complications sooner.
As additional lawsuits continue to be filed, the federal courts have consolidated many of these claims into a multidistrict litigation (MDL) to streamline discovery and other pretrial proceedings. Understanding where the litigation stands today can help patients better evaluate their legal options and what to expect moving forward.
Key Takeaways About GLP-1 Lawsuits
- The GLP-1 multidistrict litigation includes lawsuits involving several medications, including Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus.
- Plaintiffs allege manufacturers failed to adequately warn about serious gastrointestinal complications associated with these medications.
- The federal litigation continues to grow as new cases are filed and coordinated discovery moves forward.
- No global GLP-1 settlement has been announced as of mid 2026.
- Medical records documenting the prescribed medication, diagnosis, and resulting injuries are important evidence when evaluating a potential claim.
What Is the Latest GLP-1 Lawsuit Update?
- In 2026, GLP-1 lawsuits continue to expand as thousands of plaintiffs pursue claims involving Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 receptor agonist medications.
- The lawsuits allege that manufacturers failed to adequately warn patients and healthcare providers about serious gastrointestinal complications, including gastroparesis (stomach paralysis), bowel obstruction, and gallbladder disease.
- The litigation is a federal multidistrict litigation (MDL) in which individual lawsuits share coordinated pretrial proceedings while each plaintiff maintains a separate claim.
What is the Current Status of the GLP-1 Lawsuits?
The GLP-1 litigation has become one of the fastest-growing pharmaceutical mass torts in the country. Thousands of lawsuits involving multiple manufacturers were coordinated by the Judicial Panel on Multidistrict Litigation in a federal multidistrict litigation (MDL) before Judge Karen Marston in the United States District Court for the Eastern District of Pennsylvania.
Rather than handling similar cases separately in federal courts across the country, the MDL allows the parties to coordinate discovery, expert testimony, and other pretrial proceedings while preserving each plaintiff's individual lawsuit. This approach helps improve efficiency without combining all claims into a single class action.
As of mid 2026, approximately 3,848 cases are pending in the federal gastrointestinal injury MDL, and additional lawsuits continue to be filed as more patients learn about the litigation. Currently, the focus remains on coordinated discovery and case development before representative bellwether trials are selected.
The litigation currently stands at the following stage:
| Litigation Milestone | Current Status |
| Federal GLP-1 MDL | Active in the Eastern District of Pennsylvania |
| Coordinated discovery | Ongoing |
| Pending federal cases | Approximately 3,848 |
| Global settlementBellwether trials set | None announced as of 2026No trials scheduled yet |
As with other multidistrict litigations, the court's scheduling orders may change as discovery progresses and additional rulings are issued.
Which Medications Are Included in the GLP-1 Litigation?
Although many people may have only heard about an Ozempic lawsuit, the current litigation involves several medications within the broader class of GLP-1 receptor agonists. Depending on the circumstances, lawsuits may involve medications manufactured by either Novo Nordisk or Eli Lilly.
| Medication | Manufacturer |
| Ozempic® | Novo Nordisk |
| Wegovy® | Novo Nordisk |
| Rybelsus® | Novo Nordisk |
| Mounjaro® | Eli Lilly |
| Zepbound® | Eli Lilly |
While each medication has its own FDA-approved uses and prescribing information, many lawsuits raise similar allegations involving serious gastrointestinal complications. Whether a particular medication is involved in an individual claim depends on the patient's prescription history, medical records, and the injuries allegedly suffered after treatment.
Contact us today for a free, no-obligation case evaluation
Why Are People Filing GLP-1 Lawsuits?
The GLP-1 lawsuits allege that manufacturers of certain medications failed to adequately warn patients and healthcare providers about the risk of serious gastrointestinal complications. Plaintiffs claim they developed severe digestive injuries after taking GLP-1 receptor agonists and that stronger safety warnings could have helped them recognize symptoms sooner or make different treatment decisions.
It is important to understand that the litigation does not allege that every person who takes a GLP-1 medication will experience these complications. Millions of patients have used these medications successfully for diabetes management and weight loss without serious side effects.
Instead, each lawsuit focuses on the specific injuries allegedly suffered by each individual patient and whether the manufacturer provided adequate warnings about those potential risks.
What Injuries Are Being Alleged in the GLP-1 Litigation?
Although every case is different, the lawsuits generally involve patients who developed significant gastrointestinal complications after taking medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, or Zepbound.
Some of the most commonly reported injuries include:
| Reported Injury | Description |
| Gastroparesis (stomach paralysis) | Delayed stomach emptying that can interfere with digestion |
| Ileus or bowel obstruction | A blockage or interruption in the normal movement of the intestines |
| Severe nausea and vomiting | Persistent symptoms that may require emergency medical treatment |
| Gallbladder disease | Gallstones, inflammation, or gallbladder removal surgery |
| Malnutrition and dehydration | Complications resulting from prolonged digestive problems |
For some patients, these conditions required repeated emergency room visits, hospitalization, additional diagnostic testing, or surgery. Others report that severe gastrointestinal symptoms interfered with their ability to work, maintain adequate nutrition, or continue treatment for diabetes or obesity.
What Does the Medical Research Say About GLP-1 Medications?
The lawsuits rely in part on a growing body of medical literature examining the gastrointestinal effects associated with GLP-1 receptor agonists.
One frequently cited study published in the Journal of the American Medical Association (JAMA) reported an increased risk of serious gastrointestinal events—including gastroparesis, bowel obstruction, and pancreatitis—among patients using GLP-1 medications for weight loss compared with certain alternative treatments. While the study did not conclude that every reported injury was caused by these medications, it contributed to ongoing discussion within the medical community about potential gastrointestinal risks.
Researchers continue to study these medications because gastrointestinal side effects can occur for many different reasons, including underlying medical conditions, other medications, and individual patient factors. As a result, the lawsuits generally focus on whether manufacturers provided adequate warnings rather than alleging the medications inevitably cause these complications in every patient.
FDA Safety Information
The U.S. Food and Drug Administration (FDA) has also updated prescribing information for certain GLP-1 medications as additional safety information has become available. Product labeling has evolved over time to reflect known gastrointestinal risks and other potential adverse events identified through ongoing clinical research and post-market safety monitoring.
Patients should continue taking prescribed medications only as directed by their healthcare provider and should promptly report persistent vomiting, severe abdominal pain, or other concerning symptoms that develop during treatment.
Has There Been a GLP-1 Lawsuit Settlement?
Many people considering filing a GLP-1 lawsuit want to know whether manufacturers have reached a settlement. As of mid 2026, no global settlement has been announced for the federal GLP-1 multidistrict litigation. The cases remain in coordinated discovery, and the litigation continues to develop as additional lawsuits are filed and the parties prepare for future bellwether proceedings.
While multidistrict litigation sometimes resolves through negotiated settlements, there is no reliable way to predict whether or when that will occur. Any future compensation awards would likely depend on the specific facts of each plaintiff's case, including the medication involved, the injuries alleged, the medical evidence, and the damages sustained.
Who May Qualify for a GLP-1 Lawsuit?
Every potential GLP-1 lawsuit must be evaluated on its own facts, but many claims involve individuals who were prescribed a GLP-1 receptor agonist and later developed serious gastrointestinal complications that required medical treatment.
Potential eligibility often depends on factors such as the medication prescribed, the nature and timing of the injury, and the available medical documentation. Simply taking Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication does not automatically create a legal claim. Instead, personal injury attorneys typically evaluate whether there is evidence connecting the medication to the alleged injury and whether the patient experienced significant damages as a result.
How Medical Records Can Support a Legal Claim
One of the most important pieces of evidence in these cases is the patient's medical history. Hospital records, physician notes, diagnostic imaging, prescription records, and gastrointestinal testing may help establish when symptoms began, what diagnosis was made, and what treatment became necessary.
Patients sometimes assume that personal journals, social media posts, or weight-loss photographs will serve as the strongest evidence. While those materials may help illustrate how the injury affected daily life, medical records generally provide the most objective documentation of the condition itself.
Attorneys and courts will rely on records showing emergency room visits, gastric emptying studies, endoscopies, surgical procedures, or treatment by gastroenterologists to provide the legal foundation of a potential claim. Future settlement offers or jury verdicts will depend heavily on the medical records provided by the plaintiff’s attorneys.
Discover how a single post can jeopardize your payout by reading our quick guide on how social media affects your personal injury claim.
Frequently Asked Questions About the GLP-1 Lawsuit
Can I File a Lawsuit If I Took Wegovy or Mounjaro Instead of Ozempic?
Possibly. The federal litigation includes allegations involving several GLP-1 receptor agonist medications, not just Ozempic. Whether you may qualify depends on the medication you used, the injuries you experienced, and the specific facts surrounding your case.
What If I Stopped Taking the Medication Before Learning About the Lawsuit?
Many people did not connect their gastrointestinal symptoms to a GLP-1 medication until months or even years after stopping treatment. If you experienced serious digestive complications after using one of these medications, it may still be worthwhile to learn about your legal options. An experienced dangerous drug attorney can review the timing of your treatment and injuries to determine whether you may still have a viable claim.
Will Filing a Lawsuit Affect My Current Medical Treatment?
A product liability lawsuit is separate from your medical care. Patients should continue following the advice of their healthcare providers and should never stop or change a prescribed medication without first discussing the decision with their physician.
The purpose of these lawsuits is to address alleged failures to warn and compensate individuals who suffered qualifying injuries—not to replace medical advice.
How Long Will the GLP-1 Litigation Take?
Large pharmaceutical multidistrict litigations often take several years to progress through discovery, bellwether trials, and potential settlement discussions. While no one can predict the exact timeline, the litigation remains active, and the court continues to move the cases through the pretrial process.
Contact The Russo Firm to Learn More About the GLP-1 Litigation
Serious gastrointestinal injuries can have lasting effects on your health, your ability to work, and your quality of life. If you experienced complications after taking Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or another GLP-1 medication, learning about your legal rights may help you make informed decisions about your next steps.
The Russo Firm represents individuals and families harmed by dangerous drugs and defective products. Our attorneys are monitoring developments in the GLP-1 litigation and can evaluate whether your circumstances may qualify for a product liability claim.
Contact The Russo Firm today at (561) 270-0913 for a free consultation and learn more about the current status of the GLP-1 litigation and your potential legal options.